摘要:Objective To observe the effects of Modified Changpu Yujin Decoction on blood-brain barrier permeability and the contents of IL-6,IL-1β in brain of rats with acute-and-chronic liver failure( ACLF). Methods 30 Wistar rats were randomly divided into control group,model group and Modified Changpu Yujin Decoction group( administration group),the model rats of hepatic fibrosis were induced by human serum albumin,and then treated with D-Gal N/LPS combined with intraperitoneal injection to establish acute and chronic hepatic failure rat model. After the modeling was completed, the administration group was treated with Modified Changpu Yujin Decoction for 5 days before the attack. The normal group and the model group were treated with 0. 9% sodium chloride injection for 5 days. And all groups were put to death 8 hours after the acute attack. HE staining and electron microscopy were used to observe the pathological changes of liver and brain in each group. The expression of Interleukin-6( IL-6) and interleukin-1β( IL-1β) were detected by ELISA and Caveolin-1,ZO-1 and P-glycoprotein( P-gp) were detected by Western blot in brain of each group. Results Compared with the model group,Modified Changpu Yujin Decoction could reduce neuronal damage and cerebral vascular edema,decreased the expression of IL-6 and IL-1β in brain tissue of ACLF rats( P < 0. 05 or P < 0. 01),and decreased the expression of Caveolin-1,P-gp and ZO-1 in the brain( P < 0. 05). Conclusion The Modified Changpu Yujin Decoction could have protective effect on the neuron and alleviate microvascular edema. The possible mechanism could be to open the blood-brain barrier and increase the concentration of drugs in the brain to exert anti-inflammatory effects.
摘要:Objective To study the effects of Jichuan Decoction on plasma substance P( SP),interstitial cells of Cajal( ICC),colonial motility of model rats with slow transit constipation,to speculate the mechanism of the effectiveness of this drug on slow transit constipation,in order to provide appropriate dosage in clinical treatment. Methods The model of slow transit constipation rats was established and were given small,medium and high doses of Jichuan Decoction respectively,meanwhile,the model group and the blank control group were also established,the stool wet weight,body weight,the contents of plasma SP and intestinal tissue c-kit mRNA were determined,and the results were statistically analyzed. Results The average value of stool wet weight of three Jichuan Decoction groups was higher than that of the constipation model group,and that of the small dose group was statistically different from that of the model group( P < 0. 05). The mean weight of rats of Jichuan decoction groups was lower than that of the model group,and there was a statistically significant difference between the medium dose group and the model group( P < 0. 05). The first defecation time of the three groups was shorter than that of the model group( P < 0. 05). The intestinal motility of three Jichuan Decoction groups was larger than that of model group and there was a statistically significant difference between the medium dose group and the model group( P < 0. 05). There was a statistical difference between the high-dose group and model group( P < 0. 01). Plasma SP content of model group was lower than that of the three groups of Jichuan Decoction,There was a statistical difference between the high-dose group and model group( P < 0. 05). The c-kit mRNA content of intestinal tissues of model group was lower than that of the three groups of Jichuan Decoction,there was a significant difference between the model group and the medium-dose group( P < 0. 05) and there was a highly significant difference between the model group and the high-dose group( P < 0. 01). Conclusion Jichuan Decoction may improve intestinal peristalsis and constipation of rats with STC by affecting SP,ICC content and fecal water content of rats,and theadministration of drugs are dosage dependent within the scope of drug dosage in the test.
关键词:Jichuan Decoction;slow transit constipation;substance P;interstitial cells of Cajal;Colonial motility;rat
摘要:目的采用Meta分析的方法评价血栓通联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法计算机检索中国知网、万方、维普和Pub Med数据库从2001年1月——2017年7月公开发表的有关血栓通联合依达拉奉治疗急性脑梗死的临床随机对照研究,采用Rev Man 5.3软件进行分析。结果最终符合纳入标准的文献共30篇。Meta分析显示:在西医常规治疗基础上加用血栓通联合依达拉奉能够有效治疗急性脑梗死(OR=4.04;95%CI:3.15,5.17;P<0.01),明显降低患者HINSS评分(MD=-3.74;95%CI:-4.20,-3.29;P<0.01)、CSS评分(MD=-6.55;95%CI:-7.24,-5.87;P<0.01),提高ESS评分(MD=7.07;95%CI:4.12,10.03;P<0.01)与Barthel评分(MD=9.31;95%CI:8.00,10.62;P<0.01)。安全性方面:治疗组14例出现不良反应,对照组6例出现不良反应。结论血栓通联合依达拉奉治疗急性脑梗死疗效明确,不良反应少,临床应用安全。